Patient no. | Age (y) | Sex | Indication for 18F-FDG PET/CT | Perihilar SUVmax | Perihilar SUV75% | Histology | Outcome |
---|---|---|---|---|---|---|---|
1 | 63 | F | Staging before surgery | 3.9 | 3.1 | CC | Curative resection |
2 | 46 | M | Staging before surgery | 5.2 | 4.3 | CC | Curative resection |
3 | 68 | M | Staging before surgery | 6.1 | 5.1 | CC | Curative resection |
4 | 66 | F | Staging before surgery | 6.6 | 5.6 | CC | Curative resection |
5 | 71 | M | Staging before PDT | 5.2 | 4.2 | CC | Stable disease |
6 | 75 | M | Staging before PDT | 6.3 | 5.2 | CC | Stable disease |
7 | 76 | M | Staging before PDT | 9.8 | 8.2 | CC | Stable disease |
Tx control after PDT | 11.0 | 9.0 | CC | Disease progress on CT 5 mo later | |||
8 | 77 | F | Tx control after PDT | 15.8 | 11.8 | CC | Disease progress on CT 6 mo later |
9 | 76 | M | Tx control after PDT | 5.2 | 4.3 | CC | Stable disease for 6 mo |
Follow-up after 6 mo | 7.1 | 5.9 | CC | Disease progress on CT 7 mo later | |||
10 | 61 | F | Tx control after PDT | 3.9 | 3.2 | CC | Disease progress on CT 9 mo later |
11 | 64 | F | Tx control after PDT | 5.0 | 4.1 | CC | Disease progress on CT 14 mo later |
12 | 78 | F | Exclusion of CC* | 4.2 | 3.5 | CC | Curative resection |
13 | 64 | M | Exclusion of CC* | 3.2 | 2.7 | No CC | 12-mo follow-up negative |
14 | 82 | F | Exclusion of CC* | 2.7 | 2.2 | No CC | 18-mo follow-up negative |
15 | 59 | M | Exclusion of CC* | 3.0 | 2.2 | No CC | 20-mo follow-up negative |
16 | 63 | M | Exclusion of CC* | 2.9 | 2.3 | No CC | 21-mo follow-up negative |
17 | 60 | M | PSC, exclusion of CC* | 3.1 | 2.4 | No CC | 18-mo follow-up negative |
18 | 35 | F | PSC, exclusion of CC* | 2.7 | 2.2 | No CC | 19-mo follow-up negative |
19 | 37 | F | PSC, exclusion of CC* | 2.5 | 2.1 | No CC | 20-mo follow-up negative |
20 | 71 | F | Tx control after PDT of CC | 3.0 | 2.5 | No CC | 18-mo follow-up negative |
↵* To avoid surgery when 18F-FDG PET/CT gave no evidence of malignancy.
CC = cholangiocarcinoma; Tx = therapy.